Drug Half-Life Assay
New York, 11967
Pharmacokinetics (PK) properties are often critical to the success of a therapeutic, and previous reports have suggested ~15% of Phase 1 clinical studies fail due to inadequate PK or pharmacodynamics properties. This is especially true for antibodies, where typically longer half-lives are desired for therapeutics to decrease dosing frequency and increase efficacy. Conversely, a short half-life may be desired for in vivo diagnostic mAbs where toxicity and off-target effects should be reduced. Creative Biolabs has a comprehensive drug half-life assay technology platform including both in vitro and in vivo drug half-life detection services to help our customers accelerate their drug development process.
5 out of 5 from 1 reviews